What is F/TAF and a detailed introduction to its main clinical effects and indications

F/TAF, Emtricitabine/Tenofovir Alafenamide compound preparation. This drug is a nucleoside reverse transcriptase inhibitor (NRTIs). By inhibiting the activity of viral reverse transcriptase, it blocks the process of converting viral RNA into DNA, thereby inhibiting viral replication. F/TAF is a new combination drug in the field of HIV treatment. Compared with traditional tenofovir disoproxil disoproxil (TDF), it has the advantages of higher safety in the kidneys and bones, and the drug concentration is more concentrated in lymphoid tissue.

Dakohua synergistically inhibits HIV-1 viral replication, reduces viral load, improves immune system function, and reduces the risk of AIDS-related complications. Tenofovir disoproxil (TAF) is the prodrug of TDF. It can be converted into the active form in the body after oral administration and preferentially exerts its effects in viral target cells. This ensures the efficacy while reducing the peak blood concentration and reducing the adverse effects on the kidneys and bone density. Fultegravir fumarate (FTC) further inhibits viral replication by blocking viral DNA chain elongation. The combined effect of the two significantly enhances the antiviral effect.

Dacovide is mainly used for the antiviral treatment of HIV-1 infection. It is suitable for adults and adolescents (≥12 years old, weight ≥35kg) who are new to treatment or have received antiretroviral treatment in the past. The drug can also be used for HIV prevention (PrEP), effectively reducing the risk of infection in high-risk groups. Clinical trials have shown that the F/TAF regimen has shown good efficacy in reducing plasma viral load, increasing CD4+T cell count and improving quality of life, while having a low incidence of adverse reactions.

With TraditionTDFCompared with the regimen, Dakovo has the advantages of low renal and bone toxicity, good tolerance, convenient oral administration, and can be taken once a day. Patients still need to pay attention to regular monitoring of renal function and hematology indicators during use, take medication as directed by the doctor, and avoid missing doses or stopping medication without authorization. For patients with renal insufficiency or taking nephrotoxic drugs, the dose should be adjusted under the guidance of a physician. In addition, F/TAF is a prescription drug and must be obtained through regular medical institutions or pharmacies to ensure that the source of the drug is safe and reliable.

Reference link:https://www.drugs.com